Advertisement

Topics

STAT Plus: Why it’s the timing, not the total sum, that matters most in Roivant’s big deal

13:58 EDT 9 Aug 2017 | STAT

Roivant, a would-be biopharma empire, scored a $1.1 billion investment. That's a big sum. It's also a huge vote of confidence in an as-yet-unproved idea.

Original Article: STAT Plus: Why it’s the timing, not the total sum, that matters most in Roivant’s big deal

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Why it’s the timing, not the total sum, that matters most in Roivant’s big deal"

Quick Search
Advertisement